Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIO OTCMKTS:CVSI OTCMKTS:GLUC NASDAQ:GTBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$4.30-6.9%$4.14$3.22▼$53.10$7.48M2.9697,567 shs47,182 shsCVSICV Sciences$0.04+1.4%$0.03$0.02▼$0.06$6.74M0.6263,327 shs45,335 shsGLUCGlucose Health$0.10-2.5%$0.09$0.08▼$0.42$1.70M1.876,749 shs1,175 shsGTBPGT Biopharma$2.06+1.5%$2.70$1.72▼$4.10$6.74M1.48250,905 shs38,391 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics0.00%+3.61%+10.54%-63.24%-73.75%CVSICV Sciences0.00%-8.75%+23.73%+31.29%-25.51%GLUCGlucose Health0.00%-0.51%+7.73%+8.21%-73.65%GTBPGT Biopharma0.00%-7.62%-29.93%-9.25%-25.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics3.2008 of 5 stars3.55.00.00.00.01.70.6CVSICV SciencesN/AN/AN/AN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma1.4027 of 5 stars3.81.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 3.00Buy$60.001,295.35% UpsideCVSICV Sciences 0.00N/AN/AN/AGLUCGlucose Health 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00433.98% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$40K187.05N/AN/A$7.10 per share0.61CVSICV Sciences$15.70M0.43N/AN/A$0.01 per share3.65GLUCGlucose Health$380K4.47N/AN/AN/A∞GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/11/2025 (Estimated)CVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/AGLUCGlucose Health-$320K-$0.03N/A∞N/A-82.29%N/AN/AN/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)Latest GLUC, GTBP, CVSI, and CDIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GTBPGT Biopharma-$0.68N/AN/AN/AN/AN/A8/11/2025N/ACDIOCardio Diagnostics-$1.80N/AN/AN/A$0.08 millionN/A5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A19.4719.47CVSICV Sciences0.261.140.30GLUCGlucose HealthN/AN/AN/AGTBPGT BiopharmaN/A0.730.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%CVSICV SciencesN/AGLUCGlucose HealthN/AGTBPGT Biopharma8.15%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%CVSICV Sciences3.80%GLUCGlucose HealthN/AGTBPGT Biopharma3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableGLUCGlucose Health147,00017.41 millionN/ANot OptionableGTBPGT Biopharma83.27 million3.16 millionNo DataGLUC, GTBP, CVSI, and CDIO HeadlinesRecent News About These CompaniesGT Biopharma, Inc. (GTBP) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comGTBP GT Biopharma, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comGT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of DirectorsJune 15, 2025 | nasdaq.comGT Biopharma Appoints New Member to its Board of DirectorsJune 13, 2025 | globenewswire.comStocks in play: GT Biopharma, Inc.May 19, 2025 | ca.finance.yahoo.comThis Natural Killer Treatment Could Help Transform How Cancer is TreatedMay 19, 2025 | baystreet.caGT Biopharma, Inc. Advances to Cohort 2 in Phase 1 Trial of GTB-3650 Following Successful Safety Review of Cohort 1May 19, 2025 | quiverquant.comQGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsMay 19, 2025 | globenewswire.comGT Biopharma Inc.May 18, 2025 | marketwatch.comGT Biopharma appoints new board memberMay 16, 2025 | investing.comGT Biopharma adds Hilary Kramer to Board of DirectorsMay 15, 2025 | investing.comGT Biopharma announces private placement dealMay 14, 2025 | investing.comGT Biopharma Appoints New Member to its Board of DirectorsMay 14, 2025 | globenewswire.comGT Biopharma Issues Warrant to Cytovance for Services RenderedApril 6, 2025 | investing.comGT Biopharma files to sell 625,283 shares of common stock for holdersMarch 7, 2025 | markets.businessinsider.comGT Biopharma to Participate in the 10th Anniversary of the Innate Killer SummitMarch 4, 2025 | markets.businessinsider.comGT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy TweakFebruary 26, 2025 | msn.comGT Biopharma, Inc. Announces Exercise of Warrants for Common Stock, Anticipating $0.7 Million in Gross ProceedsFebruary 25, 2025 | quiverquant.comQGT Biopharma Announces Exercise of WarrantsFebruary 25, 2025 | globenewswire.comGT Biopharma could report Phase 1 trial data later this year, says Roth MKMFebruary 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUC, GTBP, CVSI, and CDIO Company DescriptionsCardio Diagnostics NASDAQ:CDIO$4.30 -0.32 (-6.93%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.22 -0.09 (-1.98%) As of 07/18/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.CV Sciences OTCMKTS:CVSI$0.04 +0.00 (+1.39%) As of 07/18/2025 02:34 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Glucose Health OTCMKTS:GLUC$0.10 0.00 (-2.50%) As of 07/18/2025 02:52 PM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.GT Biopharma NASDAQ:GTBP$2.06 +0.03 (+1.48%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.06 0.00 (0.00%) As of 07/18/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
